NEW YORK, Dec. 19, 2006 (PRIME NEWSWIRE) -- National Stem Cell Holding, Inc. (Pink Sheets:NHGI) announced that Michael Cohen, CEO, was recently interviewed by Angela Gonzales, Senior Reporter of The Business Journal - Phoenix. The front page print article can be found online at: http://phoenix.bizjournals.com/phoenix/stories/2006/12/04/story3.html?b=1165208400%5e1383449&surround=etf. Further details about National Stem Cell Holding, Inc. can be found on the company profile link on the InvestSource Communications website at: http://investsourceinc.com/php/clients.php
In the interview, Mr. Cohen discussed the nature of National Stem Cell's business and some recent developments from the company. National Stem Cell is working on the development of potential stem cell therapies for the treatment of diabetes and cardiac injury through its sponsored research agreement with the Johns Hopkins University School of Medicine's Institute for Cell Engineering. The company is also planning to open a genetically diverse umbilical cord blood bank to meet the growing need for transplant grade umbilical cord blood stem cells. Mr. Cohen explained, "cord blood stem cells already are recognized as a viable treatment for more than 80 diseases, a number that will continue to grow . . . We're hoping to be able to establish a research facility as well as a laboratory and provide laboratory services within your state in conjunction with a currently existing company," Cohen said, "But there is no definitive agreement I can speak about at this point." More information on the company is available at: www.nationalstemcell.com
About National Stem Cell Holding, Inc.
National Stem Cell Holding, Inc. (Pink Sheets:NHGI) is a biotechnology company headquartered in New York City dedicated to the advancement of regenerative medicine. Incorporated in 2005, National Stem Cell Holding, Inc. is the parent company of National Stem Cell, Inc., which operates the Sperm Bank of New York as a wholly owned subsidiary. Through its sponsored research agreement with the Johns Hopkins University School of Medicine's Institute for Cell Engineering, National Stem Cell is focused on the development of potential stem cell therapies for the treatment of diabetes and cardiac injury. The company is developing a genetically diverse umbilical cord blood bank to meet the growing need for transplant grade umbilical cord blood stem cells. For more information, please visit www.nationalstemcell.com.
Forward-Looking Statements: As provided by the "Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995," National Stem Cell Holding, Inc. cautions readers that this email includes certain information which may constitute forward-looking statements. The materials on this email that address the company's financial or business outlook apply only as of the date the information was issued. The outlook may not be current, therefore, it should be used as background information only. This press release contains forward-looking statements regarding the Company's financial or business outlook. Such statements are based on management's current beliefs and expectations. There are a number of risks and uncertainties that could cause actual results or events to differ materially from management's current beliefs and expectations. National Stem Cell Holding, Inc. does not undertake any obligation to update forward-looking statements.